l-Histidinol Provides Effective Selection of Retrovirus-Vector-Transduced Keratinocytes Without Impairing Their Proliferative Potential
- 1 April 1991
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 2 (1) , 33-39
- https://doi.org/10.1089/hum.1991.2.1-33
Abstract
Retroviral vectors carrying the neomycin phosphotransferase (neo) gene have been shown to confer G418 resistance to canine keratinocytes at relatively high frequency. To investigate the usefulness of keratinocytes as potential target cells for gene therapy, we used a retroviral vector (LASN) that contains both human adenosine deaminase (hADA) and neo genes. We show here that LASN-transduced canine keratinocytes expressed high levels of hADA, a human protein of therapeutic relevance. Selection of LASN-transduced keratinocytes in medium containing G418 resulted in a population of cells that expressed even higher levels of hADA, about 80-fold higher than the endogenous canine ADA level. However, the G418-selected cells had a reduced proliferative potential and altered morphology indicative of terminal differentiation. To test whether l-histidinol is more beneficial for selection of keratinocytes than G418, we constructed two retroviral vectors that contain both the neo and the histidinol dehydrogenase (hisD) genes. Cocultivation of primary keratinocytes with lethally irradiated PA317 retrovirus packaging cells that produce these vectors gave rise to 12–53% drug-resistant colonies in either G418 or l-histidinol. In contrast to G418, selection of transduced keratinocytes in l-histidinol had no apparent effect on the proliferative potential or morphology of drug-resistant cells containing the vectors. Given the utility of this selection system, two hisD-based generic constructs containing cloning sites for cDNA expression from either the retroviral promoter or from an internal human cytomegalovirus immediate early promoter were constructed. Our results suggest that hisD will be a useful selectable marker for use in studies of keratinocyte differentiation and for transfer of genes into keratinocytes for the purposes of gene therapy. For many purposes it is useful to have a selectable marker gene (as well as the gene of interest) in a retroviral vector. The neo gene has been used by many investigators. The authors demonstrate that for their particular target cells (canine keratinocytes) G418 selection for expression of the neo gene is detrimental. They show that histidinol selection for expression of the hisD gene provides a better selection system. The implication of this study is that the selectable marker gene might have to be chosen to match the properties of the target cell.Keywords
This publication has 23 references indexed in Scilit:
- Retrovirus Packaging CellsHuman Gene Therapy, 1990
- Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial WallScience, 1989
- High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral VectorsScience, 1989
- Two dominant-acting selectable markers for gene transfer studies in mammalian cells.Proceedings of the National Academy of Sciences, 1988
- Expression of an Exogenous Growth Hormone Gene by Transplantable Human Epidermal CellsScience, 1987
- Factors involved in production of helper virus-free retrovirus vectorsSomatic Cell and Molecular Genetics, 1986
- Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/W miceCell, 1985
- Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5Gene, 1982
- Evidence for the existence of two types of cAMP binding sites in aggregating cells of dictyostelium discoideumCell, 1975
- A modification of the mallory connective tissue stain as a stain for keratinOral Surgery, Oral Medicine, Oral Pathology, 1963